ADPT
Adaptive Biotechnologies Corp
28.40$
+3.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 60.6% | 62.0% | 60.3% | 60.1% | 55.2% | 52.6% | 50.2% | 52.7% | 57.4% | 58.5% | 57.7% | 65.6% | |
| 12.4% | 9.8% | 11.5% | 10.2% | 6.8% | 8.9% | 9.9% | 8.7% | 11.2% | 13.7% | 15.3% | 26.5% | |
| 51.7% | 52.4% | 49.8% | 49.9% | 43.6% | 41.2% | 37.9% | 39.8% | 43.4% | 44.3% | 43.2% | 53.7% | |
| 4.3% | 5.7% | 6.8% | 6.1% | 7.3% | 7.7% | 8.5% | 8.9% | 9.4% | 9.8% | 9.5% | 7.7% | |
| 2.7% | 2.2% | 2.1% | 2.3% | 2.1% | 1.6% | 1.7% | 1.7% | 2.0% | 1.9% | 2.2% | 1.6% | |
| 16.6% | 18.0% | 19.2% | 20.3% | 21.3% | 22.1% | 23.3% | 24.0% | 24.2% | 23.2% | 23.5% | 18.6% | |
| 0.8% | 0.8% | 0.8% | 0.7% | 0.7% | 0.6% | 0.6% | 0.5% | 0.4% | 0.3% | 0.3% | 0.1% | |
| 49.6% | 53.4% | 55.7% | 58.7% | 60.0% | 62.5% | 62.8% | 63.8% | 58.4% | 56.1% | 55.7% | 76.5% | |
| 13.0% | 13.3% | 13.4% | 15.1% | 15.7% | 18.2% | 17.2% | 18.6% | 17.0% | 17.5% | 17.2% | 13.7% | |
| 1.3% | 1.4% | 1.5% | 1.7% | 1.8% | 1.9% | 2.0% | 2.0% | 1.9% | 2.6% | 2.8% | 1.4% | |
| 0.6% | 1.2% | 2.0% | 1.7% | 1.3% | 1.3% | 1.2% | 1.4% | 2.1% | 1.3% | 1.9% | 0.8% | |
| – | – | – | – | – | – | – | – | – | – | – | 52.3% | |
| 50.4% | 46.6% | 44.3% | 41.3% | 40.1% | 37.6% | 37.3% | 36.2% | 41.7% | 42.7% | 42.8% | 22.3% | |
| -149.8% | -173.1% | -192.1% | -211.7% | -227.4% | -241.7% | -261.1% | -273.7% | -275.1% | -265.9% | -273.4% | -222.1% | |
| 20.2% | 21.9% | 23.5% | 25.2% | 26.4% | 27.3% | 29.2% | 30.6% | 33.3% | 29.9% | 30.7% | 24.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.